Symbols / NVCT
NVCT Chart
About
Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 238.96M |
| Enterprise Value | 198.84M | Income | -28.87M | Sales | — |
| Book/sh | 0.72 | Cash/sh | 1.19 | Dividend Yield | — |
| Payout | 0.00% | Employees | 13 | IPO | — |
| P/E | — | Forward P/E | -9.40 | PEG | — |
| P/S | — | P/B | 12.58 | P/C | — |
| EV/EBITDA | — | EV/Sales | — | Quick Ratio | 2.38 |
| Current Ratio | 2.38 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -1.32 | EPS next Y | -0.96 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-05-05 | ROA | -68.50% |
| ROE | -188.03% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 26.49M |
| Shs Float | 15.49M | Short Float | 10.26% | Short Ratio | 21.18 |
| Short Interest | — | 52W High | 11.52 | 52W Low | 5.55 |
| Beta | -0.30 | Avg Volume | 79.06K | Volume | 25.73K |
| Target Price | $16.80 | Recom | Strong_buy | Prev Close | $8.70 |
| Price | $9.02 | Change | 3.68% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$16.80
Mean price target
2. Current target
$9.02
Latest analyst target
3. DCF / Fair value
$-4.64
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$9.02
Low
$10.00
High
$20.00
Mean
$16.80
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-08-04 | main | HC Wainwright & Co. | Buy → Buy | $10 |
| 2025-04-30 | reit | HC Wainwright & Co. | Buy → Buy | $15 |
| 2025-04-02 | init | Maxim Group | — → Buy | $17 |
| 2025-03-17 | init | Laidlaw & Co. | — → Buy | $19 |
| 2025-02-25 | main | HC Wainwright & Co. | Buy → Buy | $11 |
| 2024-08-06 | reit | HC Wainwright & Co. | Buy → Buy | $21 |
| 2024-05-08 | reit | HC Wainwright & Co. | Buy → Buy | $21 |
| 2023-09-15 | reit | HC Wainwright & Co. | Buy → Buy | $21 |
| 2023-03-07 | reit | HC Wainwright & Co. | — → Buy | $21 |
| 2023-02-10 | reit | HC Wainwright & Co. | — → Buy | $21 |
| 2022-07-13 | init | Ladenburg Thalmann | — → Buy | $21 |
| 2022-05-10 | main | HC Wainwright & Co. | — → Buy | $21 |
| 2022-03-02 | init | HC Wainwright & Co. | — → Buy | $14 |
- (NVCT) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily Fri, 20 Feb 2026 04
- Nuvectis Pharma Reports 2025 Financial Results and Progress in NXP900 Development Program - Quiver Quantitative Wed, 11 Feb 2026 08
- Insiders of Nuvectis Pharma, Inc. (NASDAQ:NVCT) must be disappointed as stock fell 10% after recent purchases - Yahoo Finance Wed, 18 Jun 2025 07
- A US$22m Market Cap Boost Pleasing ToNuvectis Pharma Insiders - simplywall.st hu, 30 Oct 2025 07
- Analysts Offer Insights on Healthcare Companies: Nuvectis Pharma (NVCT), Tenet Healthcare (THC) and Upstream Bio, Inc. (UPB) - The Globe and Mail Fri, 13 Feb 2026 08
- Nuvectis Pharma director Sanchez buys $75k in NVCT stock - Investing.com hu, 06 Nov 2025 08
- Insider Purchase: Chairman & CEO of $NVCT Buys 5,000 Shares - Quiver Quantitative hu, 06 Nov 2025 08
- Nuvectis Pharma: Still Interesting, But Still Too Risky To Jump In - Seeking Alpha Wed, 18 Jun 2025 07
- Precision Trading with Nuvectis Pharma Inc. (NVCT) Risk Zones - Stock Traders Daily Mon, 15 Dec 2025 08
- Nuvectis Pharma, Inc.'s (NASDAQ:NVCT) market cap rose US$18m last week; individual investors who hold 44% profited and so did insiders - simplywall.st Fri, 05 Dec 2025 08
- Prime Medicine is selling $125M in stock; Nuvectis stops work on ovarian cancer drug - Endpoints News hu, 31 Jul 2025 07
- Will NVCT stock reach all time highs in 2025 - Quarterly Trade Summary & AI Driven Price Predictions - mfd.ru Wed, 11 Feb 2026 09
- Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail hu, 12 Feb 2026 08
- Why Nuvectis Pharma, Inc. (NVCT) is Surging in 2025 - Yahoo Finance Wed, 30 Apr 2025 07
- Insider Purchase: 10% owner at $NVCT Buys 72,836 Shares - Quiver Quantitative Wed, 29 Oct 2025 07
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 150000 | — | — | Stock Award(Grant) at price 0.00 per share. | BENTSUR RON | Chief Executive Officer | — | 2026-01-06 00:00:00 | D |
| 1 | 150000 | — | — | Stock Award(Grant) at price 0.00 per share. | SHEMESH SHAY | Officer | — | 2026-01-06 00:00:00 | D |
| 2 | 150000 | — | — | Stock Award(Grant) at price 0.00 per share. | PORADOSU ENRIQUE | Officer | — | 2026-01-06 00:00:00 | D |
| 3 | 61200 | — | — | Stock Award(Grant) at price 0.00 per share. | CARSON MICHAEL J. | Officer | — | 2026-01-06 00:00:00 | D |
| 4 | 5000 | 28600 | — | Purchase at price 5.72 per share. | BENTSUR RON | Chief Executive Officer | — | 2025-11-05 00:00:00 | D |
| 5 | 11000 | 64240 | — | Purchase at price 5.84 per share. | KAPLAN MATTHEW L. | Director | — | 2025-11-05 00:00:00 | D |
| 6 | 13000 | 75270 | — | Purchase at price 5.79 per share. | SANCHEZ JUAN | Director | — | 2025-11-05 00:00:00 | D |
| 7 | 154770 | 957083 | — | Purchase at price 6.06 - 6.28 per share. | MOSSERI MARLIO CHARLES | Beneficial Owner of more than 10% of a Class of Security | — | 2025-10-27 00:00:00 | I |
| 8 | 30000 | — | — | Stock Award(Grant) at price 0.00 per share. | SANCHEZ JUAN | Director | — | 2025-09-22 00:00:00 | D |
| 9 | 5603 | 44768 | — | Purchase at price 7.99 per share. | MOSSERI MARLIO CHARLES | Beneficial Owner of more than 10% of a Class of Security | — | 2025-06-20 00:00:00 | I |
Financials
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -27.57M | -19.85M | -22.90M | -19.23M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -26.44M | -19.00M | -22.26M | -19.09M |
| EBITDA | -27.57M | -19.85M | -22.90M | -19.23M |
| EBIT | -27.57M | -19.85M | -22.90M | -19.23M |
| NetInterestIncome | 1.13M | 847.00K | 637.00K | 149.00K |
| InterestIncome | 1.13M | 847.00K | 637.00K | 149.00K |
| NormalizedIncome | -26.44M | -19.00M | -22.26M | -19.09M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -26.44M | -19.00M | -22.26M | -19.09M |
| TotalExpenses | 27.57M | 19.85M | 22.90M | 19.23M |
| TotalOperatingIncomeAsReported | -27.57M | -19.85M | -22.90M | -19.23M |
| DilutedAverageShares | 17.11M | 15.56M | 12.66M | 12.72M |
| BasicAverageShares | 17.11M | 15.56M | 12.66M | 12.72M |
| DilutedEPS | -1.11 | -1.43 | -1.51 | -1.09 |
| BasicEPS | -1.11 | -1.43 | -1.51 | -1.09 |
| DilutedNIAvailtoComStockholders | -28.87M | -19.00M | -22.26M | -19.09M |
| NetIncomeCommonStockholders | -28.87M | -19.00M | -22.26M | -19.09M |
| OtherunderPreferredStockDividend | 2.43M | 0.00 | ||
| NetIncome | -26.44M | -19.00M | -22.26M | -19.09M |
| NetIncomeIncludingNoncontrollingInterests | -26.44M | -19.00M | -22.26M | -19.09M |
| NetIncomeContinuousOperations | -26.44M | -19.00M | -22.26M | -19.09M |
| PretaxIncome | -26.44M | -19.00M | -22.26M | -19.09M |
| NetNonOperatingInterestIncomeExpense | 1.13M | 847.00K | 637.00K | 149.00K |
| InterestIncomeNonOperating | 1.13M | 847.00K | 637.00K | 149.00K |
| OperatingIncome | -27.57M | -19.85M | -22.90M | -19.23M |
| OperatingExpense | 27.57M | 19.85M | 22.90M | 19.23M |
| ResearchAndDevelopment | 18.15M | 12.92M | 15.38M | 13.23M |
| SellingGeneralAndAdministration | 9.42M | 6.93M | 7.52M | 6.01M |
| GeneralAndAdministrativeExpense | 9.42M | 6.93M | 7.52M | 6.01M |
| OtherGandA | 6.40M | 4.23M | 4.38M | 3.07M |
| InsuranceAndClaims | 599.00K | 606.00K | 842.00K | 1.18M |
| SalariesAndWages | 2.42M | 2.09M | 2.30M | 1.76M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 25.68M | 19.50M | 17.42M | 14.64M |
| ShareIssued | 25.68M | 19.50M | 17.42M | 14.64M |
| TangibleBookValue | 18.41M | 9.71M | 12.20M | 14.22M |
| InvestedCapital | 18.41M | 9.71M | 12.20M | 14.22M |
| WorkingCapital | 18.41M | 9.71M | 12.20M | 14.22M |
| NetTangibleAssets | 18.41M | 9.71M | 12.20M | 14.22M |
| CommonStockEquity | 18.41M | 9.71M | 12.20M | 14.22M |
| TotalCapitalization | 18.41M | 9.71M | 12.20M | 14.22M |
| TotalEquityGrossMinorityInterest | 18.41M | 9.71M | 12.20M | 14.22M |
| StockholdersEquity | 18.41M | 9.71M | 12.20M | 14.22M |
| RetainedEarnings | -99.69M | -73.25M | -54.24M | -31.98M |
| AdditionalPaidInCapital | 118.10M | 82.96M | 66.45M | 46.20M |
| CapitalStock | 0.00 | 0.00 | 0.00 | 0.00 |
| CommonStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 13.30M | 8.89M | 6.98M | 6.19M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 0.00 | 0.00 | 0.00 | 0.00 |
| PreferredSecuritiesOutsideStockEquity | 0.00 | 15.25M | ||
| CurrentLiabilities | 13.30M | 8.89M | 6.98M | 6.19M |
| PensionandOtherPostRetirementBenefitPlansCurrent | 6.91M | 5.56M | 3.80M | 2.38M |
| PayablesAndAccruedExpenses | 6.39M | 3.34M | 3.19M | 3.81M |
| CurrentAccruedExpenses | 115.00K | 840.00K | 415.00K | 445.00K |
| Payables | 6.27M | 2.50M | 2.77M | 3.36M |
| OtherPayable | 450.00K | 824.00K | ||
| AccountsPayable | 6.27M | 2.50M | 2.77M | 2.91M |
| TotalAssets | 31.71M | 18.61M | 19.18M | 20.41M |
| TotalNonCurrentAssets | 0.00 | 0.00 | 0.00 | 0.00 |
| NonCurrentDeferredAssets | 0.00 | 824.00K | ||
| CurrentAssets | 31.71M | 18.61M | 19.18M | 20.41M |
| OtherCurrentAssets | 75.00K | 74.00K | 59.00K | 412.00K |
| CashCashEquivalentsAndShortTermInvestments | 31.63M | 18.53M | 19.13M | 19.99M |
| CashAndCashEquivalents | 31.63M | 18.53M | 19.13M | 19.99M |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -16.01M | -12.25M | -15.95M | -13.56M |
| IssuanceOfCapitalStock | 31.21M | 12.04M | 5.29M | 31.88M |
| InterestPaidSupplementalData | 0.00 | |||
| IncomeTaxPaidSupplementalData | 0.00 | |||
| EndCashPosition | 31.63M | 18.53M | 19.13M | 19.99M |
| BeginningCashPosition | 18.53M | 19.13M | 19.99M | 5.74M |
| ChangesInCash | 13.10M | -593.00K | -867.00K | 14.25M |
| FinancingCashFlow | 29.11M | 11.65M | 15.09M | 27.81M |
| CashFlowFromContinuingFinancingActivities | 29.11M | 11.65M | 15.09M | 27.81M |
| NetOtherFinancingCharges | -2.10M | -382.00K | -1.39M | -4.07M |
| ProceedsFromStockOptionExercised | 0.00 | 11.19M | 0.00 | |
| NetPreferredStockIssuance | 0.00 | 15.25M | ||
| PreferredStockIssuance | 0.00 | 15.25M | ||
| NetCommonStockIssuance | 31.21M | 12.04M | 5.29M | 31.88M |
| CommonStockIssuance | 31.21M | 12.04M | 5.29M | 31.88M |
| InvestingCashFlow | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingCashFlow | -16.01M | -12.25M | -15.95M | -13.56M |
| CashFlowFromContinuingOperatingActivities | -16.01M | -12.25M | -15.95M | -13.56M |
| ChangeInWorkingCapital | 4.40M | 1.90M | 1.60M | 3.82M |
| ChangeInOtherWorkingCapital | 1.35M | 1.76M | 1.42M | 1.95M |
| ChangeInOtherCurrentAssets | -1.00K | -15.00K | 353.00K | -321.00K |
| ChangeInPayablesAndAccruedExpense | 3.05M | 152.00K | 1.25M | 4.14M |
| ChangeInAccruedExpense | -725.00K | 425.00K | 1.39M | 2.29M |
| ChangeInPayable | 3.78M | -273.00K | -139.00K | 1.85M |
| ChangeInAccountPayable | 3.78M | -273.00K | -139.00K | 1.85M |
| StockBasedCompensation | 6.03M | 4.86M | 4.71M | 1.71M |
| NetIncomeFromContinuingOperations | -26.44M | -19.00M | -22.26M | -19.09M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for NVCT
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|